ACELLULAR PERTUSSIS VACCINES

Year 2001, Volume: 14 Issue: 2, 131 - 133, 03.12.2016

Dilşad Cebeci

Abstract

Pertussis is a dangerous infectious disease that is well controlled world-wide by widespread immunization. The major cause of the decline in the morbidity and mortality of the disease is the intensive World Health Organization's Expanded Program on Immunization. However, pertussis still remains one of major diseases because of its high morbidity; an estimated 40 million pertussis cases occurred worldwide in 1994, resulting in 5 million episodes of pneumonia, 360000 deaths, and 50000 neurological complications (including permanent brain damage).

References

• /. Strebel PM, Guris D, Wassilak SGP. Pertussis. In: Maxcy-Rosenau-Last, eds. Public Health â Preventing Medicine. 14th ed. Connecticut: Appleton and Lange, 1998; 98-101.
• Decker MD, Edwards KM. Acellular pertussis vaccines. Pediatr Cli north Am 2000; 42: 309- 335.
• Cherry JD, Mortimer EA Jr, Hackell JG and the Multicenter Vaccine Study Groups: Clinical Trials in the United States and Japan with the Lederia-Takeda and Takeda acellular pertussis-diphtheria-tetanus (APDT) vaccines Dev Biol Stand I991;73:5I-??
• Gustafsson L, Hollander HO, Olin P, Reizenstein E, Storsaeter J. A controlled trial of a two-component acellular, a five component acellular, and a whole cell pertussis vaccine. H Eng J Med 1996; 334: 349-355.
• Greco D, Salmaso S, Mastranonio P, Gluliano M, Tozzi AE, Anemona A. A controlled trial of two acellular vaccines and one whole cell vaccine against pertussis. H Eng J Med 1996; 333: 1045-1050.
• Schmitt HJ, Wirsing Von Konig CH, Heiss A, et al. Efficacy of acellular pertussis vaccine in early childhood after household exposre. JAMA 1996; 275: 37-41.
• Decker MD, Edwards KM, Steinhoff MC, Rennels MB, Plchichero ME, Enflung JA. Comparison of 13 acellular pertussis vaccines: adverse reactions. Pediatrics 1995: 96 (Suppl): 557-566.
• Taranger J, Trollfors B, Lagergard T. Mass vaccination with a monocomponent pertussis toxoid vaccine in a defined geographic area (abstract G-8). In Programs and Abstracts of the 37 th Interscience Conference of Antimicrobial Agents and Chemotherpy 1997, Toronto, Ontario, Canada.
• Taranger J, Trollfors B, Lagergard T. Unchanged efficacy of a pertussis toxoid vaccine throughout the two years after the third vaccination of infants. Pediatr Infect Dis J 1997; 16: 180-??
• Ad hoc Group for the Study of Pertussis Vaccines: Placebo-controlled trial of two acellular pertussis vaccines in Sweden: Protective efficacy and adverse events. Lancet 1988; 1: 955-
• Edwards KM, Decker MD, Barney S. Adult immunization with acellular pertussis vaccine JAMA 1993; 269: 53-56.
• Keitel WA. Cellular and acellular pertussis vaccines in adults. Clin Infect Dis 199; 28(Suppl 2): SI 18-23.
• Centers for Disease Control and Prevention: Diphteria, tetanus and pertussis: Recommended childhood immunization Schedule-United States. Recommendations for vaccine use and other preventive measures. Recommendations of the advisory committee on Immunization Practices (ACIP).MMWR Morb Mortal Wkly Rep 1999; 48: 12s.